Pharma

The Readout Elaine Chen

STAT Plus: A new drug for glioma means a windfall for Agios

Pharma Andrew Joseph

STAT Plus: Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report

The Readout Elaine Chen

STAT Plus: The exclusive biotech stories you need to read

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a canceled Roche trial, low VC biotech funding, and more

Exclusive Elizabeth Cohen

STAT Plus: ‘Jerking families around’: Canceled Roche rare disease trial devastates parents, angers researchers

Pharmalot Ed Silverman

STAT Plus: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about MDMA trials, weight loss drug availability, and more

The Readout Meghana Keshavan

STAT Plus: FDA ad comm favors Zevra’s Niemann-Pick drug

Health tech Katie Palmer

STAT Plus: Weight loss drugs without a prescription? Study warns it’s a ‘very risky business’

Pharmalot Jonathan Wosen

STAT Plus: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more

The Readout Elaine Chen

STAT Plus: Moderna is still in a Covid hangover

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: On Andrew Left and the government’s fraud case

The Readout Elaine Chen

STAT Plus: venBio raises $528 million for its fifth fund

Pharmalot Andrew Joseph

STAT Plus: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more

The Readout Elaine Chen

STAT Plus: The debate over how long to use Alzheimer’s drugs

Pharmalot Allison DeAngelis

STAT Plus: Pharmalittle: We’re watching GLP-1 drug data in Alzheimer’s, a flu shot push for livestock workers, and more

Pharmalot Bob Herman and Ed Silverman

STAT Plus: Wells Fargo faces class action lawsuit over workers’ high drug costs

Pharmalot Ed Silverman

STAT Plus: NIH loses suit over censoring social media comments made by animal rights advocates

The Readout Elaine Chen

STAT Plus: Testing GLP-1s in Alzheimer’s, and is Medicare a good negotiator?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about the U.K. nixing coverage for a cancer drug, sharing bird flu vaccine data, and more

Politics John Wilkerson

STAT Plus: How to tell if Biden drove a hard bargain in Medicare drug price negotiations

The Readout Meghana Keshavan

STAT Plus: The biotech news you need from the weekend

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Sarepta’s demand to censor a video, Roche fast-tracking an obesity pill, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a thumbs down for an Alzheimer’s drug, Pfizer gene therapy struggles, and more

The Readout Elaine Chen

STAT Plus: The worst for Dexcom may not be over

Pharma Jason Mast

STAT Plus: How Pfizer’s grand gene therapy ambitions crumbled

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: The state pharma’s targeting this election cycle

Health tech Mario Aguilar

STAT Plus: Six questions about Medicare’s proposed plan to cover digital therapeutics